Afaf Osman, MD
Institution
Huntsman Cancer Center, University of Utah
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes (MDS)
Alex Nester, MD
Institution
University of Nebraska Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
High Risk MDS Non-Transplant Therapies Current Therapies and Clinical Trials Omaha Patient and Family Hybrid Conference 2023
Topic(s)
Myelodysplastic Syndromes (MDS)
High Risk MDS Non-Transplant Therapies Current Therapies and Clinical Trials with Dr. Prajwal Dhakal
Amanda Przespolewski, DO
Institution
Roswell Park Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Srinivas Tantravahi, MBBS, MRCP
Institution
Huntsman Cancer Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Tantravahi has received his medical degree from Guntur medical college, India. He then completed Internal Medicine residency and Hematology and Oncology fellowship training at University of Utah Hospital. His clinical interests include multiple myeloma, stem cell transplantation, and myeloproliferative neoplasm. Research interests are targeted therapy in CML and myeloproliferative neoplasms.
Updates from ASH22 on MDS and AML
Topic(s)
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
In this webinar, Dr. Lourdes Mendez discusses research most relevant to patients reported over the past year on the biology and treatment on MDS and secondary AML. These studies were presented at the American Society of Hematology (ASH) 2022 meeting. Research findings are…
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Original Publication Date
Article Source
External Web Content
ABSTRACT PURPOSE Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve…
Damian Laber, MD
Institution
Moffit Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Laber is a hematologist/oncologist and senior member with Moffitt Medical Group in the Satellite and Community Oncology Department practicing at Tampa General Hospital and Moffitt international Plaza. The MMG faculty at TGH provides invaluable oncology services to the large patient population of this leading regional hospital. Dr. Laber earned his M.D. at the University of Buenos Aires, Argentina. He completed his residency in internal medicine at Cleveland Clinic Health System, and was designated Chief Resident during his term at Hillcrest and Southpointe Hospitals. Dr. Laber’s research
2022 Miami Patient and Family Hybrid Conference: Transplantation for Bone Marrow Failure
Topic(s)
Bone Marrow Transplant
Presenter(s)
Antonio Jimenez Jimenez, MD
Bone marrow transplantation is rigorous, so understanding the challenges from the process is essential. Learn from Dr. Antonio Jimenez Jimenez all about what patients can expect when this treatment is selected.